NEWSROOM
News & Stories
Newsroom
Press Releases
Agendia Responds to “Clinical Insights on MINDACT”
ย Dear Dr. Febbo, I recently received an email from you, in which you provided your unsolicited โClinical Insights on MINDACTโ. ย I have been a practicing medical oncologist for nearly 30 years, the last 20 Read More
New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy
46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrintยฎ Read More
New Data Shows Agendiaโs MammaPrint can Prevent Under and Over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score
The PRospective study Of MammaPrint in breast cancer patients with an Intermediate recurrence Score (PROMIS) included 840 women at 58 US institutions. 45% of patients with an intermediate/indeterminate Recurrence Score from a 21-gene assay OncotypeDx Read More